Compare FN & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FN | INSM |
|---|---|---|
| Founded | 1999 | 1988 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 23.0B |
| IPO Year | 2007 | 2000 |
| Metric | FN | INSM |
|---|---|---|
| Price | $481.17 | $109.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 24 |
| Target Price | ★ $513.43 | $201.17 |
| AVG Volume (30 Days) | 826.3K | ★ 3.7M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.21 | N/A |
| EPS | ★ 9.22 | N/A |
| Revenue | ★ $3,419,327,000.00 | N/A |
| Revenue This Year | $36.87 | $182.31 |
| Revenue Next Year | $17.91 | $65.19 |
| P/E Ratio | $51.38 | ★ N/A |
| Revenue Growth | ★ 18.60 | N/A |
| 52 Week Low | $272.49 | $90.39 |
| 52 Week High | $748.89 | $212.75 |
| Indicator | FN | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 37.13 | 51.94 |
| Support Level | $429.50 | $98.90 |
| Resistance Level | $508.51 | $166.81 |
| Average True Range (ATR) | 33.08 | 4.67 |
| MACD | -3.31 | 1.13 |
| Stochastic Oscillator | 18.70 | 46.19 |
Fabrinet provides advance-level optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and sub-systems, industrial lasers, automotive components, medical devices, and sensors. The company offers a broad range of advance optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, complex printed circuit board assembly, advance-level of packaging, integration, final assembly, and testing. The company generates the majority of its revenue from North America and Asia-Pacific, with the rest from Europe.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.